Retatrutide Dual-Chamber Pen 60 mg (USA domestic)

This is not a premixed pen.

Each pen contains:

• 60 mg lyophilized Retatrutide (powder)
• Bacteriostatic water for injection

The components remain separated until activation. The solution is mixed immediately prior to administration.

Key Benefits

• Not premixed — stored in a stable unmixed dry form
• Mixes instantly before use
• No syringes or measuring required
• Lower risk of dosing errors

This system combines the reliability of lyophilized peptides with the simplicity of a ready-to-use pen.

About Retatrutide

Retatrutide is a new weekly weight loss injection that’s still in development. Like other popular GLP-1s, it helps you feel full so you naturally eat less.

The difference is in how it works. Retatrutide has been nicknamed “Triple G” because it activates three key hormones at once: GLP-1, GIP, and GCG (glucagon). This triple effect may make it the most powerful option yet  and early studies back that up. 

In a phase II trial, people lost an average of 24.2% of their body weight in just 48 weeks at the highest dose. That’s more than the results seen with Wegovy (~14.9% at 68 weeks) or Mounjaro (~21% at 72 weeks).

• Triple-receptor activation: targets GLP-1, GIP, and glucagon pathways for enhanced appetite suppression, improved insulin sensitivity, increased energy expenditure, and accelerated fat loss.
• Ready-to-use premixed pen: no vials or reconstitution; simply dial, click, and inject subcutaneously.
• Precision dosing: each click delivers 0.1 mg, with a transparent window showing remaining volume.
• Capacity: 300 clicks × 0.1 mg = 30 mg total.
• Quality: ≥ 99% purity, endotoxin < 0.03 EU/mg, sterilized, tamper-evident, scratch-code verified.

Dosing Information (Based on Clinical Trials)

Retatrutide does not yet have an official approved dosing schedule, as it is still in development. However, phase II studies have used the following titration approach:

• Starting dose: 1 mg or 2 mg weekly
• Dose escalation: Increase every 4 weeks
• Maximum dose studied: 12 mg weekly
• Maintenance dose in studies: varied between 4 mg and 12 mg weekly, depending on individual tolerance and goals

Example escalation from trials:
1-4 weeks → 1 mg
5-8 weeks → 2 mg
9-12 weeks → 4 mg
13-16 weeks → 8 mg
17+ weeks → up to 12 mg (if tolerated)

Notes:

• Always escalate gradually (every 4 weeks) to reduce GI side effects.
• Skip escalation if the current dose is well-tolerated but effective.
• Administer once weekly, same day each week, subcutaneously in the abdomen, thigh, or upper arm.
• Refrigerate at 35-40°F after mixing.

Administration Guide

Will be added soon.